Teriflunomide and its mechanism of action in multiple sclerosis

Drugs

Volumn 74, Issue 6, 2014, Pages 659-674

  Bar Or, Amit ^a   Pachner, Andrew ^b   Menguy Vacheron, Francoise ^c   Kaplan, Johanne ^c   Wiendl, Heinz ^d  

^a MCGILL UNIVERSITY   (Canada)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^c SANOFI   (France)

^d UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; CELL ADHESION MOLECULE; CHEMOKINE RECEPTOR CCR6; CYCLIN DEPENDENT KINASE 2; DIHYDROOROTATE DEHYDROGENASE; DNA; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; LEFLUNOMIDE; LIPOPOLYSACCHARIDE; MATRIX METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; TERIFLUNOMIDE; TUMOR NECROSIS FACTOR ALPHA; CROTONIC ACID DERIVATIVE; ENZYME INHIBITOR; IMMUNOLOGIC FACTOR; OXIDOREDUCTASE; TOLUIDINE DERIVATIVE;

ADAPTIVE IMMUNITY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLELE; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIINFLAMMATORY ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ASTROCYTE; AXONAL INJURY; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; BLOOD BRAIN BARRIER; BRAIN TISSUE; CD4+ T LYMPHOCYTE; CELL CYCLE ARREST; CELL CYCLE S PHASE; CELL DEATH; CELL FUNCTION; CELL PROLIFERATION; CELL VIABILITY; CENTRAL NERVOUS SYSTEM; CLINICAL STUDY; CYTOKINE RELEASE; CYTOKINE RESPONSE; CYTOMEGALOVIRUS INFECTION; DEMYELINATION; DENDRITIC CELL; DIARRHEA; DISEASE ACTIVITY; DISEASE COURSE; DNA SYNTHESIS; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; EVOKED MUSCLE RESPONSE; EVOKED SOMATOSENSORY RESPONSE; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; HAIR DISEASE; HAIR THINNING; HELPER CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS C; HERPES ZOSTER; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; IMMUNOCOMPETENCE; IMMUNOCOMPETENT CELL; IMMUNOGLOBULIN PRODUCTION; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; INCIDENCE; INFLAMMATION; INFLUENZA VACCINATION; LEUKOCYTE COUNT; LIVER INJURY; LYMPHOCYTE; LYMPHOCYTE MIGRATION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MAJOR HISTOCOMPATIBILITY COMPLEX; MICROGLIA; MUCOSA CELL; MULTIPLE SCLEROSIS; MURINE ENCEPHALOMYELITIS VIRUS; MUTAGENICITY; NATURAL KILLER CELL; NAUSEA; NERVE FUNCTION; NEUTROPHIL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PREGNANCY; PROSPECTIVE STUDY; PROTEIN AGGREGATION; PYRIMIDINE SYNTHESIS; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SEASONAL INFLUENZA; SIDE EFFECT; SPINAL CORD; SPLEEN WEIGHT; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TERATOGENICITY; TH17 CELL; TH2 CELL; TUBERCULOSIS; UPREGULATION; VASCULAR ENDOTHELIUM; VIRUS LOAD; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; IMMUNOLOGY; PATHOPHYSIOLOGY;

ANIMALS; B-LYMPHOCYTES; CELL PROLIFERATION; CROTONATES; ENZYME INHIBITORS; HUMANS; IMMUNOLOGIC FACTORS; MULTIPLE SCLEROSIS; OXIDOREDUCTASES ACTING ON CH-CH GROUP DONORS; T-LYMPHOCYTES; TOLUIDINES;

EID: 84899856893     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-014-0212-x     Document Type: Review

References (184)

1. Hauser SL, Oksenberg JR. The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron. 2006;52:61-76.
2. Trapp BD, Nave KA. Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci. 2008;31:247-69.
3. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol. 2005;23:683-747.
4. McFarland HF, Martin R. Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol. 2007;8:913-9.
5. Hafler DA. Multiple sclerosis. J Clin Invest. 2004;113:788-94.
6. Liblau RS, Gonzalez-Dunia D, Wiendl H, et al. Neurons as targets for T cells in the nervous system. Trends Neurosci. 2013.
7. Dutta R, Trapp BD. Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis. Prog Neurobiol. 2011;93:1-12.
8. Lucchinetti CF, Popescu BF, Bunyan RF, et al. Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med. 2011;365:2188-97.
9. O'Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365:1293-303.
10. Confavreux C, O'Connor P, Comi G, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13:247-56.
11. Frischer JM, Bramow S, Dal-Bianco A, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain. 2009;132:1175-89.
12. Christensen JR, Bornsen L, Ratzer R, et al. Systemic inflammation in progressive multiple sclerosis involves follicular T-helper, th17- and activated B-cells and correlates with progression. PLoS One. 2013;8:e57820.
13. Melzer N, Meuth SG, Wiendl H. CD8+ T cells and neuronal damage: direct and collateral mechanisms of cytotoxicity and impaired electrical excitability. FASEB J. 2009;23:3659-73.
14. Kerlero de Rosbo N, Milo R, Lees MB, et al. Reactivity to myelin antigens in multiple sclerosis. Peripheral blood lymphocytes respond predominantly to myelin oligodendrocyte glycoprotein. J Clin Invest. 1993;92:2602-8.
15. Ransohoff RM, Kivisakk P, Kidd G. Three or more routes for leukocyte migration into the central nervous system. Nat Rev Immunol. 2003;3:569-81.
16. Galea I, Bernardes-Silva M, Forse PA, et al. An antigen-specific pathway for CD8 T cells across the blood-brain barrier. J Exp Med. 2007;204:2023-30.
17. Archambault AS, Sim J, Gimenez MA, et al. Defining antigen-dependent stages of T cell migration from the blood to the central nervous system parenchyma. Eur J Immunol. 2005;35:1076-85.
18. Reboldi A, Coisne C, Baumjohann D, et al. C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat Immunol. 2009;10:514-23.
19. Arima Y, Harada M, Kamimura D, et al. Regional neural activation defines a gateway for autoreactive T cells to cross the blood-brain barrier. Cell. 2012;148:447-57.
20. Hohlfeld R, Wekerle H. Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines. Proc Natl Acad Sci USA. 2004;101(Suppl 2):14599-606.
21. Hohlfeld R. Multiple sclerosis: human model for EAE? Eur J Immunol. 2009;39:2036-9.
22. Ben-Nun A, Wekerle H, Cohen IR. The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis. Eur J Immunol. 1981;11:195-9.
23. Beecham AH, Patsopoulos NA, Xifara DK, et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet. 2013;45:1353-60.
24. Panitch HS, Hirsch RL, Haley AS, et al. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet. 1987;1:893-5.
25. Gutcher I, Becher B. APC-derived cytokines and T cell polarization in autoimmune inflammation. J Clin Invest. 2007;117:1119-27.
26. Kebir H, Kreymborg K, Ifergan I, et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med. 2007;13:1173-5.
27. McKenzie BS, Kastelein RA, Cua DJ. Understanding the IL-23-IL-17 immune pathway. Trends Immunol. 2006;27:17-23.
28. Tzartos JS, Friese MA, Craner MJ, et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol. 2008;172:146-55.
29. Darlington PJ, Touil T, Doucet JS, et al. Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation. Ann Neurol. 2013;73:341-54.
30. Friese MA, Fugger L. Pathogenic CD8(+) T cells in multiple sclerosis. Ann Neurol. 2009;66:132-41.
31. Brisebois M, Zehntner SP, Estrada J, et al. A pathogenic role for CD8+ T cells in a spontaneous model of demyelinating disease. J Immunol. 2006;177:2403-11.
32. Traugott U, Reinherz EL, Raine CS. Multiple sclerosis: distribution of T cell subsets within active chronic lesions. Science. 1983;219:308-10.
33. Crawford MP, Yan SX, Ortega SB, et al. High prevalence of autoreactive, neuroantigen-specific CD8+ T cells in multiple sclerosis revealed by novel flow cytometric assay. Blood. 2004;103:4222-31.
34. Zozulya AL, Wiendl H. The role of CD8 suppressors versus destructors in autoimmune central nervous system inflammation. Hum Immunol. 2008;69:797-804.
35. Zozulya AL, Wiendl H. The role of regulatory T cells in multiple sclerosis. Nat Clin Pract Neurol. 2008;4:384-98.
36. Bjerg L, Brosbol-Ravnborg A, Torring C, et al. Altered frequency of T regulatory cells is associated with disability status in relapsing-remitting multiple sclerosis patients. J Neuroimmunol. 2012;249:76-82.
37. Colombo M, Dono M, Gazzola P, et al. Accumulation of clonally related B lymphocytes in the cerebrospinal fluid of multiple sclerosis patients. J Immunol. 2000;164:2782-9.
38. Krumbholz M, Derfuss T, Hohlfeld R, et al. B cells and antibodies in multiple sclerosis pathogenesis and therapy. Nat Rev Neurol. 2012;8:613-23.
39. von Budingen HC, Bar-Or A, Zamvil SS. B cells in multiple sclerosis: connecting the dots. Curr Opin Immunol. 2011;23:713-20.
40. Serafini B, Rosicarelli B, Magliozzi R, et al. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol. 2004;14:164-74.
41. Lovato L, Willis SN, Rodig SJ, et al. Related B cell clones populate the meninges and parenchyma of patients with multiple sclerosis. Brain. 2011;134:534-41.
42. von Budingen HC, Kuo TC, Sirota M, et al. B cell exchange across the blood-brain barrier in multiple sclerosis. J Clin Invest. 2012;122:4533-43.
43. Duddy M, Niino M, Adatia F, et al. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol. 2007;178:6092-9.
44. Bar-Or A, Fawaz L, Fan B, et al. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? Ann Neurol. 2010;67:452-61.
45. Barr TA, Shen P, Brown S, et al. B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J Exp Med. 2012;209:1001-10.
46. Ray A, Mann MK, Basu S, et al. A case for regulatory B cells in controlling the severity of autoimmune-mediated inflammation in experimental autoimmune encephalomyelitis and multiple sclerosis. J Neuroimmunol. 2011;230:1-9.
47. Iwata Y, Matsushita T, Horikawa M, et al. Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood. 2011;117:530-41.
48. Kalampokis I, Yoshizaki A, Tedder TF. IL-10-producing regulatory B cells (B10 cells) in autoimmune disease. Arthritis Res Ther. 2013;15(Suppl 1):S1.
49. Correale J, Farez M, Razzitte G. Helminth infections associated with multiple sclerosis induce regulatory B cells. Ann Neurol. 2008;64:187-99.
50. Nuyts A, Lee W, Bashir-Dar R, et al. Dendritic cells in multiple sclerosis: key players in the immunopathogenesis, key players for new cellular immunotherapies? Mult Scler. 2013.
51. Chanvillard C, Jacolik RF, Infante-Duarte C, et al. The role of natural killer cells in multiple sclerosis and their therapeutic implications. Front Immunol. 2013;4:63.
52. Brosnan CF, Raine CS. The astrocyte in multiple sclerosis revisited. Glia. 2013;61:453-65.
53. Friese MA, Fugger L. T cells and microglia as drivers of multiple sclerosis pathology. Brain. 2007;130:2755-7.
54. Alberts B, Johnson A, Lewis J, et al. Molecular biology of the cell. 4th ed. New York: Garland Science; 2002.
55. Bruneau JM, Yea CM, Spinella-Jaegle S, et al. Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide. Biochem J. 1998;336(Pt 2):299-303.
56. Cherwinski HM, Cohn RG, Cheung P, et al. The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis. J Pharmacol Exp Ther. 1995;275:1043-9.
57. Ruckemann K, Fairbanks LD, Carrey EA, et al. Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans. J Biol Chem. 1998;273:21682-91.
58. Loffler M, Klein A, Hayek-Ouassini M, et al. Dihydroorotate dehydrogenase mRNA and protein expression analysis in normal and drug-resistant cells. Nucleosides Nucleotides Nucleic Acids. 2004;23:1281-5.
59. Gold R, Wolinsky JS. Pathophysiology of multiple sclerosis and the place of teriflunomide. Acta Neurol Scand. 2011;124:75-84.
60. Jameson SC. Maintaining the norm: T-cell homeostasis. Nat Rev Immunol. 2002;2:547-56.
61. Fairbanks LD, Bofill M, Ruckemann K, et al. Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans. Disproportionate expansion of pyrimidine pools and contrasting effects of de novo synthesis inhibitors. J Biol Chem. 1995;270:29682-9.
62. Pearce EL. Metabolism in T cell activation and differentiation. Curr Opin Immunol. 2010;22:314-20.
63. Davenport L, Czich A, Turpault S. Teriflunomide: no effects on sperm DNA: ECTRIMS poster 1171. Mult Scler J. 2013;19:559-73.
64. Li L, Liu J, Delohery T, et al. The effects of teriflunomide on lymphocyte subpopulations in human peripheral blood mononuclear cells. J Neuroimmunol. 2013;265:82-90.
65. Ringshausen I, Oelsner M, Bogner C, et al. The immunomodulatory drug leflunomide inhibits cell cycle progression of B-CLL cells. Leukemia. 2008;22:635-8.
66. Cherwinski HM, McCarley D, Schatzman R, et al. The immunosuppressant leflunomide inhibits lymphocyte progression through cell cycle by a novel mechanism. J Pharmacol Exp Ther. 1995;272:460-8.
67. Siemasko KF, Chong AS, Williams JW, et al. Regulation of B cell function by the immunosuppressive agent leflunomide. Transplantation. 1996;61:635-42.
68. Rosenblatt J, Gu Y, Morgan DO. Human cyclin-dependent kinase 2 is activated during the S and G2 phases of the cell cycle and associates with cyclin A. Proc Natl Acad Sci USA. 1992;89:2824-8.
69. Quemeneur L, Gerland LM, Flacher M, et al. Differential control of cell cycle, proliferation, and survival of primary T lymphocytes by purine and pyrimidine nucleotides. J Immunol. 2003;170:4986-95.
70. Posevitz V, Chudyka D, Kurth F, et al. Teriflunomide suppresses antigen induced T-cell expansion in a TCR avidity dependent fashion (P1107). Mult Scler J. 2012;18(S4):509-20.
71. Starr TK, Jameson SC, Hogquist KA. Positive and negative selection of T cells. Annu Rev Immunol. 2003;21:139-76.
72. Bielekova B, Sung MH, Kadom N, et al. Expansion and functional relevance of high-avidity myelin-specific CD4+ T cells in multiple sclerosis. J Immunol. 2004;172:3893-904.
73. Zeyda M, Poglitsch M, Geyeregger R, et al. Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: involvement of impaired integrin activation and immunologic synapse formation. Arthritis Rheum. 2005;52:2730-9.
74. Fuentealba RA, Marasa J, Diamond MI, et al. An aggregation sensing reporter identifies leflunomide and teriflunomide as polyglutamine aggregate inhibitors. Hum Mol Genet. 2012;21:664-80.
75. Korn T, Magnus T, Toyka K, et al. Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide-mechanisms independent of pyrimidine depletion. J Leukoc Biol. 2004;76:950-60.
76. Dimitrova P, Skapenko A, Herrmann ML, et al. Restriction of de novo pyrimidine biosynthesis inhibits Th1 cell activation and promotes Th2 cell differentiation. J Immunol. 2002;169:3392-9.
77. Li L, Liu J, Zhang D, et al. Teriflunomide treatment of human monocyte-derived dendritic cells in vitro does not impair their maturation or ability to induce allogeneic T-cell responses|ECTRIMS 2012. Mult Scler J. 2012;18:279-508 (P950).
78. Claussen MC, Korn T. Immune mechanisms of new therapeutic strategies in MS: teriflunomide. Clin Immunol. 2012;142:49-56.
79. Lorentzen JC, Issazadeh S, Storch M, et al. Protracted, relapsing and demyelinating experimental autoimmune encephalomyelitis in DA rats immunized with syngeneic spinal cord and incomplete Freund's adjuvant. J Neuroimmunol. 1995;63:193-205.
80. Merrill JE, Hanak S, Pu SF, et al. Teriflunomide reduces behavioral, electrophysiological, and histopathological deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitis. J Neurol. 2009;256:89-103.
81. Ringheim G, Lee L, Laws-Ricker L, et al. Teriflunomide attenuates immunopathological changes in the Dark Agouti rat model of experimental autoimmune encephalomyelitis. Front Mult Scler Neuroimmunol. 2013;4:169.
82. Kraan MC, Reece RJ, Barg EC, et al. Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers. Arthritis Rheum. 2000;43:1820-30.
83. Petty M, Lee L, Ying X. Teriflunomide treatment reduces infiltration of macrophages, T cells and B cells, and increases survival of oligodendrocytes in the spinal cord of the Dark Agouti rat model of Experimental Allergic Encephalomyelitis. AAN 2010, 10-17 April 2010, Toronto, Canada, 2010.
84. Iglesias-Bregna D, Hanak S, Ji Z, et al. Effects of prophylactic and therapeutic teriflunomide in transcranial magnetic stimulation-induced motor-evoked potentials in the Dark Agouti rat model of experimental autoimmune encephalomyelitis. J Pharmacol Exp Ther. 2013;347:203-11.
85. Tsunoda I, Fujinami RS. Neuropathogenesis of Theiler's murine encephalomyelitis virus infection, an animal model for multiple sclerosis. J Neuroimmune Pharmacol. 2010;5:355-69.
86. Pachner A, Li L. Teriflunomide ameliorates disability progression in the Theiler's virus-induced demyelinating disease model of MS [P05.196]|AAN 2013. Neurology. 2013:P05.196.
87. Pachner A, Li L. Effect of teriflunomide on the viral load and anti-viral antibody responses in the Theiler's virus model of MS [P02.143]|AAN 2012. Neurology. 2012:P02.143.
88. O'Connor PW, Li D, Freedman MS, et al. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology. 2006;66:894-900.
89. Singer B, Comi G, Miller A, et al. Frequency of infections during treatment with teriflunomide: pooled data from three placebo-controlled teriflunomide studies|AAN 2013. Neurology. 2013.
90. Freedman M, Wolinsky JS, Comi G, et al. Long-term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. ECTRIMS 2013 Poster 544. Mult Scler J. 2013;19:74-558.
91. Confavreux C, Li DK, Freedman MS, et al. Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years. Mult Scler. 2012;18:1278-89.
92. Bar-Or A, Freedman MS, Kremenchutzky M, et al. Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis. Neurology. 2013;81:552-8.
93. (CPMP) Cfpmp. Note for guidance on harmonisation of requirements for influenza vaccines. In: Unit HME (ed) The European Agency for the Evaluation of Medicinal Products, 1997.
94. Bar-Or A, Larouche R, Legrand B, et al. Immune response to neoantigen and recall antigens in healthy subjects receiving teriflunomide. ECTRIMS Poster 622. Mult Scler J. 2013;19:74-558.
95. Ali R, Nicholas RS, Muraro PA. Drugs in development for relapsing multiple sclerosis. Drugs. 2013;73:625-50.
96. Leist T, Freedman M, Kappos L, et al. Pooled safety data from three placebo-controlled teriflunomide studies: ECTRIMS 2013 Poster 633. Mult Scler J. 2013;19:74-558.
97. Garnock-Jones KP. Teriflunomide: a review of its use in relapsing multiple sclerosis. CNS Drugs. 2013;27:1103-23.
98. Trueb RM. Chemotherapy-induced alopecia. Semin Cutan Med Surg. 2009;28:11-4.
99. LLC s-aUS. ARAVA prescribing information. Bridgewater: Sanofi-Aventis U.S. LLC; 2012.
100. Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med. 1999;159:2542-50.
101. Genzyme. AUBAGIO US prescribing information. Cambridge: Genzyme Corporation, a sanofi company; 2012.
102. Sanofi-Aventis. AUBAGIO summary of product characteristics. France: Sanofi-Aventis; 2013.
103. Chambers CD, Johnson DL, Robinson LK, et al. Birth outcomes in women who have taken leflunomide during pregnancy. Arthritis Rheum. 2010;62:1494-503.
104. Cassina M, Johnson DL, Robinson LK, et al. Pregnancy outcome in women exposed to leflunomide before or during pregnancy. Arthritis Rheum. 2012;64:2085-94.
105. Kieseier B, Benamor M, Truffinet P. Pregnancy outcomes from the teriflunomide clinical development programme: PACTRIMS 2013 Poster 79. In: 6th Congress of the Pan-Asian Committee for Treatment and Research in Multiple Sclerosis (PACTRIMS); 6-8 November 2013, Kyoto, Japan.
106. Chan A, Weilbach FX, Toyka KV, et al. Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients. Clin Exp Immunol. 2005;139:152-8.
107. Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest. 2003;111:1133-45.
108. Matloubian M, Lo CG, Cinamon G, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature. 2004;427:355-60.
109. Bauer M, Brakebusch C, Coisne C, et al. Beta1 integrins differentially control extravasation of inflammatory cell subsets into the CNS during autoimmunity. Proc Natl Acad Sci USA. 2009;106:1920-5.
110. Gan Y, Liu R, Wu W, et al. Antibody to alpha4 integrin suppresses natural killer cells infiltration in central nervous system in experimental autoimmune encephalomyelitis. J Neuroimmunol. 2012;247:9-15.
111. Wolinsky JS, Narayana PA, Nelson F, et al. Magnetic resonance imaging outcomes from a phase III trial of teriflunomide. Mult Scler. 2013.
112. Genzyme. Alemtuzumab FDA highlights of prescribing information, 2007.
113. Ontaneda D, Cohen JA. The benefits and risks of alemtuzumab in multiple sclerosis. Expert Rev Clin Immunol. 2013;9:189-91.
114. Wiendl H, Kieseier B. Multiple sclerosis: reprogramming the immune repertoire with alemtuzumab in MS. Nat Rev Neurol. 2013;9:125-6.
115. Biogen-Idec. FDA Approved Labeling Text for Tecfidera (dimethyl fumarate). 2013.
116. Scannevin RH, Chollate S, Jung MY, et al. Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. J Pharmacol Exp Ther. 2012;341:274-84.
117. Moharregh-Khiabani D, Blank A, Skripuletz T, et al. Effects of fumaric acids on cuprizone induced central nervous system de- and remyelination in the mouse. PLoS One. 2010;5:e11769.
118. Treumer F, Zhu K, Glaser R, et al. Dimethylfumarate is a potent inducer of apoptosis in human T cells. J Invest Dermatol. 2003;121:1383-8.
119. de Jong R, Bezemer AC, Zomerdijk TP, et al. Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate. Eur J Immunol. 1996;26:2067-74.
120. Peng H, Guerau-de-Arellano M, Mehta VB, et al. Dimethyl fumarate inhibits dendritic cell maturation via nuclear factor kappaB (NF-kappaB) and extracellular signal-regulated kinase 1 and 2 (ERK1/2) and mitogen stress-activated kinase 1 (MSK1) signaling. J Biol Chem. 2012;287:28017-26.
121. Vandermeeren M, Janssens S, Borgers M, et al. Dimethylfumarate is an inhibitor of cytokine-induced E-selectin, VCAM-1, and ICAM-1 expression in human endothelial cells. Biochem Biophys Res Commun. 1997;234:19-23.
122. Schilling S, Goelz S, Linker R, et al. Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Clin Exp Immunol. 2006;145:101-7.
123. Novartis. Gilenya (Fingolimod) summary of product characteristics updated 12/04/2013. 2013.
124. Mandala S, Hajdu R, Bergstrom J, et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science. 2002;296:346-9.
125. Coelho RP, Payne SG, Bittman R, et al. The immunomodulator FTY720 has a direct cytoprotective effect in oligodendrocyte progenitors. J Pharmacol Exp Ther. 2007;323:626-35.
126. Miron VE, Ludwin SK, Darlington PJ, et al. Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices. Am J Pathol. 2010;176:2682-94.
127. Kohne A, Stettner M, Jangouk P, et al. Fingolimod impedes Schwann cell-mediated myelination: implications for the treatment of immune neuropathies? Arch Neurol. 2012;69:1280-9.
128. Mullershausen F, Craveiro LM, Shin Y, et al. Phosphorylated FTY720 promotes astrocyte migration through sphingosine-1-phosphate receptors. J Neurochem. 2007;102:1151-61.
129. Xie JH, Nomura N, Koprak SL, et al. Sphingosine-1-phosphate receptor agonism impairs the efficiency of the local immune response by altering trafficking of naive and antigen-activated CD4+ T cells. J Immunol. 2003;170:3662-70.
130. TEVA-Pharmaceuticals. Copaxone (Galtiramer Acetate) full prescribing information, 2009.
131. Boster A, Bartoszek MP, O'Connell C, et al. Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis. Ther Adv Neurol Disord. 2011;4:319-32.
132. Aharoni R, Teitelbaum D, Sela M, et al. Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1. J Neuroimmunol. 1998;91:135-46.
133. Fridkis-Hareli M, Teitelbaum D, Pecht I, et al. Binding of copolymer 1 and myelin basic protein leads to clustering of class II MHC molecules on antigen-presenting cells. Int Immunol. 1997;9:925-34.
134. Vieira PL, Heystek HC, Wormmeester J, et al. Glatiramer acetate (copolymer-1, copaxone) promotes Th2 cell development and increased IL-10 production through modulation of dendritic cells. J Immunol. 2003;170:4483-8.
135. Aharoni R, Teitelbaum D, Leitner O, et al. Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1. Proc Natl Acad Sci USA. 2000;97:11472-7.
136. Teitelbaum D, Milo R, Arnon R, et al. Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein. Proc Natl Acad Sci USA. 1992;89:137-41.
137. Skihar V, Silva C, Chojnacki A, et al. Promoting oligodendrogenesis and myelin repair using the multiple sclerosis medication glatiramer acetate. Proc Natl Acad Sci USA. 2009;106:17992-7.
138. Novartis. Interferon beta (Extavia) summary of product characteristics updated 16/04/2013, 2013.
139. Bayer. Interferon beta (Betaferon) summary of product characteristics updated 05/02/2013, 2013.
140. Idec B. Interferon beta (Avonex) summary of product characteristics updated 07/02/2013, 2013.
141. Bongioanni P, Lombardo F, Moscato G, et al. T-cell interferon gamma receptor binding in interferon beta-1b-treated patients with multiple sclerosis. Arch Neurol. 1999;56:217-22.
142. Noronha A, Toscas A, Jensen MA. Interferon beta augments suppressor cell function in multiple sclerosis. Ann Neurol. 1990;27:207-10.
143. Arnason BG. Interferon beta in multiple sclerosis. Clin Immunol Immunopathol. 1996;81:1-11.
144. Vosoughi R, Freedman MS. Therapy of MS. Clin Neurol Neurosurg. 2010;112:365-85.
145. Ozenci V, Kouwenhoven M, Huang YM, et al. Multiple sclerosis is associated with an imbalance between tumour necrosis factor-alpha (TNF-alpha)- and IL-10-secreting blood cells that is corrected by interferon-beta (IFN-beta) treatment. Clin Exp Immunol. 2000;120:147-53.
146. Shapiro S, Galboiz Y, Lahat N, et al. The 'immunological-synapse' at its APC side in relapsing and secondary-progressive multiple sclerosis: modulation by interferon-beta. J Neuroimmunol. 2003;144:116-24.
147. Yushchenko M, Mader M, Elitok E, et al. Interferon-beta-1 b decreased matrix metalloproteinase-9 serum levels in primary progressive multiple sclerosis. J Neurol. 2003;250:1224-8.
148. EMD-Serono. Novotrone (mitoxantrone for injection concentrate) FDA-approved label, 2010.
149. Koeller J, Eble M. Mitoxantrone: a novel anthracycline derivative. Clin Pharm. 1988;7:574-81.
150. Burns SA, Lee Archer R, Chavis JA, et al. Mitoxantrone repression of astrocyte activation: relevance to multiple sclerosis. Brain Res. 2012;1473:236-41.
151. Fidler JM, DeJoy SQ, Gibbons JJ Jr. Selective immunomodulation by the antineoplastic agent mitoxantrone. I. Suppression of B lymphocyte function. J Immunol. 1986;137:727-32.
152. Biogen-Idec. Natalizumab (Tysabri) FDA-approved label, 2004.
153. Millonig A, Hegen H, Di Pauli F, et al. Natalizumab treatment reduces endothelial activity in MS patients. J Neuroimmunol. 2010;227:190-4.
154. Benkert TF, Dietz L, Hartmann EM, et al. Natalizumab exerts direct signaling capacity and supports a pro-inflammatory phenotype in some patients with multiple sclerosis. PLoS One. 2012;7:e52208.
155. Bornsen L, Christensen JR, Ratzer R, et al. Effect of natalizumab on circulating CD4+ T-cells in multiple sclerosis. PLoS One. 2012;7:e47578.
156. de Andres C, Teijeiro R, Alonso B, et al. Long-term decrease in VLA-4 expression and functional impairment of dendritic cells during natalizumab therapy in patients with multiple sclerosis. PLoS One. 2012;7:e34103.
157. Sanofi. Aubagio EMA summary of product characteristics, 2013.
158. Martin JF, Perry JS, Jakhete NR, et al. An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells. J Immunol. 2010;185:1311-20.
159. Martin R. Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis. Clin Immunol. 2012;142:9-14.
160. Perry JS, Han S, Xu Q, et al. Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis. Sci Transl Med. 2012;4:145ra06.
161. Wuest SC, Edwan JH, Martin JF, et al. A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. Nat Med. 2011;17:604-9.
162. Aharoni R, Saada R, Eilam R, et al. Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis. J Neuroimmunol. 2012;251:14-24.
163. Wegner C, Stadelmann C, Pfortner R, et al. Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis. J Neuroimmunol. 2010;227:133-43.
164. Toubi E, Nussbaum S, Staun-Ram E, et al. Laquinimod modulates B cells and their regulatory effects on T cells in multiple sclerosis. J Neuroimmunol. 2012;251:45-54.
165. Schulze-Topphoff U, Shetty A, Varrin-Doyer M, et al. Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity. PLoS One. 2012;7:e33797.
166. Zou LP, Abbas N, Volkmann I, et al. Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue. Neuropharmacology. 2002;42:731-9.
167. Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet. 2011;378:1779-87.
168. Barun B, Bar-Or A. Treatment of multiple sclerosis with anti-CD20 antibodies. Clin Immunol. 2012;142:31-7.
169. Aspen-Global. Azathioprine (Imuran) summary of product characteristics, 2012.
170. Elion GB. The George Hitchings and Gertrude Elion Lecture. The pharmacology of azathioprine. Ann N Y Acad Sci. 1993;685:400-7.
171. La Mantia L, Mascoli N, Milanese C. Azathioprine. Safety profile in multiple sclerosis patients. Neurol Sci. 2007;28:299-303.
172. Baxter. Cyclophosphamide summary of product characteristics, 2003.
173. Kovarsky J. Clinical pharmacology and toxicology of cyclophosphamide: emphasis on use in rheumatic diseases. Semin Arthritis Rheum. 1983;12:359-72.
174. Lutsiak ME, Semnani RT, De Pascalis R, et al. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood. 2005;105:2862-8.
175. Weiner HL, Cohen JA. Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects. Mult Scler. 2002;8:142-54.
176. Hospira. Methotrexate summary of product characteristics, 1987.
177. Bender RA, Makula DM. Effect of interaction between methotrexate and dihydrofolate reductase on DNA synthesis in L1210 cells in vitro. Br J Cancer. 1978;37:403-10.
178. Johnston A, Gudjonsson JE, Sigmundsdottir H, et al. The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol. 2005;114:154-63.
179. Spurlock CF III, Aune ZT, Tossberg JT, et al. Increased sensitivity to apoptosis induced by methotrexate is mediated by JNK. Arthritis Rheum. 2011;63:2606-16.
180. Serraj K, Federici L, Maloisel F, et al. Pancytopenia related to low-dose methotrexate: study of five cases and review of the literature. Rev Med Interne. 2007;28:584-8.
181. Roche. CellCept (mycophenolate mofetil) label, FDA approved, 2009.
182. Allison AC, Kowalski WJ, Muller CD, et al. Mechanisms of action of mycophenolic acid. Ann N Y Acad Sci. 1993;696:63-87.
183. Ritter ML, Pirofski L. Mycophenolate mofetil: effects on cellular immune subsets, infectious complications, and antimicrobial activity. Transpl Infect Dis. 2009;11:290-7.
184. Michel L, Vukusic S, De Seze J, et al. Mycophenolate mofetil in multiple sclerosis: a multicentre retrospective study on 344 patients. J Neurol Neurosurg Psychiatry. 2014;85:279-83.